Roche/Genentech Announces Locations of GENERATION HD1 Drug Study
Posted on December 20, 2018
On Wednesday, December 19th, Roche/Genentech announced the US and Canadian locations for their upcoming study to test efficacy of the huntingtin-lowering…
Read MoreHDSA’s 2018 Research Report Is Now Available
Posted on December 13, 2018
This week, HDSA published the 2018 Research Report, a written re-cap of global HD research progress and how HDSA research…
Read MoreHD Buzz on Huntingtin-Lowering Strategies
Posted on December 6, 2018
The Ionis/Roche/Genentech Huntington’s program has received a lot of press in recent months. However, several additional companies have been working…
Read MoreHappy Thanksgiving!
Posted on November 29, 2018
We hope you had a Happy Thanksgiving, and a big thank you to our readers for your interest in research…
Read MoreRoche/Genentech Announces US & Canadian Locations of Observational Natural History Study
Posted on November 15, 2018
On Saturday at the Huntington Study Group Meeting in Houston, Roche/Genentech announced the US and Canadian locations for their Natural…
Read MoreDr. Amber Southwell Featured on UCF Website
Posted on November 8, 2018
HDSA-supported researcher Dr. Amber Southwell is featured this week in an article about huntingtin-lowering. Her lab’s recent publication showed that…
Read MoreHDSA Now Accepting Applications for Two HD Research Funding Opportunities
Posted on November 1, 2018
This week, we have opened up applications for HDSA research funding. Learn about how we support HD research and pass…
Read MoreHDSA Names Five HD Human Biology Fellows For 2018
Posted on October 25, 2018
This week, we announced the winners of the 2018 HD Human Biology Fellowship. These young scientists were chosen for their…
Read MoreFAQ About Upcoming Genentech/Roche Trials
Posted on October 17, 2018
HDSA received hundreds of questions during and after the September 26th webinar presented by Genentech/Roche representatives about upcoming clinical trials….
Read MoreUpcoming HDSA Research Webinar on New Strategies for Huntingtin-Lowering
Posted on October 11, 2018
ASOs therapies have dominated the news recently, but did you know that there are many additional strategies being developed in…
Read MoreNew Study Provides Valuable Insight Into Juvenile Huntington’s Disease
Posted on October 4, 2018
When symptoms of HD start before the age of 20, this is known as juvenile onset Huntington’s disease, or JHD….
Read MoreRoche/Genentech Clinical Trial Update Webinar Available to View
Posted on September 27, 2018
If you missed the clinical trials update webinar presented by Roche on Wednesday the 26th, it’s now available for viewing…
Read MoreRoche Provides Info About Ongoing HD Program & Announces Two Upcoming Trials; HDSA to Host Webinar
Posted on September 20, 2018
This past Sunday at the plenary meeting of the European Huntington’s Disease Network (EHDN), Roche Pharmaceuticals announced some details about…
Read MoreRegister for the Upcoming HDSA Webinar with Roche/Genentech on Wed. September 26th
Posted on September 13, 2018
This week, members of the HDSA team are attending the 2018 plenary meeting of the European Huntington’s Disease Network (EHDN)…
Read MoreInterview with 2018 Berman-Topper Fellow – Dr. Rachel Harding
Posted on September 6, 2018
This week, meet Dr. Rachel Harding from the University of Toronto, the recipient of this year’s Berman-Topper Family HD Career…
Read MoreHD Featured in Science Magazine
Posted on August 30, 2018
The prestigious Science magazine published an article on Huntington’s disease this week, describing the huntingtin-lowering ASO drug developed by Ionis,…
Read MoreProposal to Streamline Gene Therapy Evaluation by the FDA
Posted on August 23, 2018
This week, the FDA released a proposal to streamline the way they oversee the evaluation of protocols related to gene…
Read MoreFirst Gene-Silencing Drug Approved by the FDA
Posted on August 16, 2018
This week marked the first FDA approval of a gene silencing drug, for a rare hereditary disease called ATTR amyloidosis….
Read MoreRoche Huntingtin-Lowering Drug Gains PRIME Status from EMA
Posted on August 7, 2018
On August 4th, Roche Pharmaceuticals announced that their huntingtin-lowering therapy was granted PRIME status from the European Medicines Agency (EMA)….
Read MoreVoice Your Opinions About The Future Of CRISPR
Posted on August 2, 2018
Community research surveys are valuable ways for researchers to get input from HD patients, families and caregivers about a variety…
Read More